QT Imaging Holdings, Inc. (QTI) generates news tied to medical device commercialization, breast imaging technology and public company reporting. The company describes itself as focused on breast health management through radiation-free imaging technology, with the Breast Acoustic CT Scanner as its main named system.
QTI news often centers on the progress of its Breast Acoustic CT platform. Relevant company updates include scanner commercialization, distribution and direct commercial activity, development work on reconstruction and quantitative imaging algorithms, clinical workflow, the QTI Precision Pathway cloud platform and collaboration related to a multimodality viewer and quantitative analysis.
Regulatory and quality-related announcements are also important for this issuer because the company operates in a medical device category. QT Imaging has announced FDA clearance for its scanner as an adjunctive breast imaging device for adult women, Israeli Ministry of Health registration for commercialization in Israel and completion of an FDA routine inspection with zero Form 483 observations.
Financial and governance news adds another layer for QTI. The company's releases and filings include quarterly financial results, financing activity, shareholder letters, annual meeting results, executive appointments and equity incentive plan matters. Regular review of QTI news helps connect the company's breast imaging technology claims with commercialization updates, regulatory disclosures and public company governance events.
QT Imaging (Nasdaq: QTI) announced AMA approval of a new Category III CPT code X579T for 3D quantitative transmission volumetric ultrasound tomography of the breast. The code will be released July 1, 2026, and becomes effective January 1, 2027, enabling standardized reporting and commercial opportunities with hospitals.
The designation recognizes the technology as a distinct clinical service, supports utilization tracking and data collection, and is described as a step toward broader reimbursement and adoption.
QT Imaging (Nasdaq: QTI) reported preliminary unaudited results for Q4 and full year 2025. Q4 revenue $8.3M on shipments of 17 scanners; 2025 revenue $18.9M on 40 scanners, above $18.0M guidance. Gross margin declined to 45% for 2025; cash and equivalents $10.5M as of Dec 31, 2025.
Strengthened capital with a $18.2M private placement, relisted on Nasdaq, and announced collaborations with Intelerad and Olea. Secured UAE distribution with committed minimum orders of 43 scanners (>$24M revenue). 2026 revenue outlook: ~$39M.
QT Imaging (NASDAQ: QTI) announced that Chief Science Officer Bilal Malik, Ph.D. will present at SPIE Medical Imaging 2026 in Vancouver, Feb 15–19, 2026. His oral talk, “Automated breast boundary extraction from reflection data in breast acoustic CT,” details a multi-step, validated algorithm integrated into company production software.
The method supports image reconstruction, reflection gain calculation, denoising, breast density calculation, and underpins planned AI/ML initiatives for lesion segmentation and clinical decision support.
QT Imaging Holdings (NASDAQ:QTI) has announced the release of a new machine learning-enabled image interpolation algorithm that reduces scan times by approximately 50%. The technology allows the system to skip alternate scan levels while maintaining high image quality and diagnostic accuracy.
The advancement aims to enhance patient comfort through shorter scanning times and improve operational efficiency by increasing patient throughput. The company will present this development at the SPIE Medical Imaging 2025 conference in San Diego.
QTI continues to expand its clinical and R&D efforts through collaborations with institutions including the National Institutes of Health, Sunnybrook Health Sciences Centre, and the Stephenson Cancer Center at the University of Oklahoma, focusing on advancing cancer detection and treatment precision.
QT Imaging Holdings (NASDAQ:QTI), a medical device company, announces the elimination of its short-term liabilities and forecasts robust revenue growth for 2025 and 2026. The company has amended its convertible promissory notes with YA II PN, and Funicular Funds, LP, extending the maturity date to March 31, 2026, with no payments due until then. QT Imaging projects revenue of $18M in 2025 and $27M in 2026, a significant increase from 2024. The company aims to deliver a minimum of 40 scanners in 2025 and 60 scanners in 2026, totaling $45M in revenue over the two years. Further details are available in the SEC Form 8-K filed on January 10, 2025.
QT Imaging Holdings (NASDAQ:QTI) has announced the expansion of its Breast Acoustic CT Scanner to Couri Center for Gynecology and Integrative Women's Health in Peoria, IL. The shipment was executed in partnership with NXC Imaging, Inc. The technology offers enhanced breast imaging capabilities, particularly beneficial for patients with dense breasts and those at elevated risk of breast cancer. The system provides painless, true 3D imaging with high resolution. QTI will present its technology at the Empowered Wellness: A Women's Health Summit on March 8, 2025, sponsored by the Couri Center.
QT Imaging Holdings (NASDAQ:QTI) announces its participation in the Radiological Society of North America 2024 Annual Meeting in Chicago, December 1-5, 2024. Dr. Bilal Malik, Chief Science Officer, will present on December 4th at 9:30 am, focusing on Breast Ultrasound Techniques. His presentation will compare quantitative transmission ultrasound imaging with digital breast tomosynthesis (DBT), showcasing results from a multi-reader, multi-case observer study.
The study demonstrates QTI's technology performs comparably to DBT, potentially offering a safe and more accessible option for breast cancer screening and diagnosis.
QT Imaging Holdings (NASDAQ: QTI) reported Q3 2024 financial results with commercial revenue of $1.0 million, including $0.9 million from scanner sales. The company achieved a gross margin of 63%, up from 51% in Q2 2024. Net loss was $3.6 million, including $1.5 million in convertible note interest expenses. The company completed an engineering and clinical feasibility study with its strategic partner and secured a $2.56 million PIPE investment from board members. QTI also amended its convertible note with YA II PN, reducing the principal balance to $8.6 million and extending maturity to March 2026.
QT Imaging Holdings (NASDAQ:QTI) has secured a $1M PIPE investment from company insiders, led by Board Chairman Dr. Avi Katz and CEO Dr. Raluca Dinu, along with four other board members. The deal includes the purchase of 4,383,558 unregistered shares at $0.584 per share with matching warrants at $0.672. Additionally, GigAcquisitions5, agreed to cancel a $1.56M promissory note. The share price represents a 10% premium over the 5-day VWAP. The financing, expected to close by November 29, 2024, will provide working capital as bridge funding while pursuing strategic partnerships and commercialization plans.
QT Imaging Holdings (NASDAQ:QTI) has received a third-year renewal of its five-year NIH/NCI research grant. The study, conducted in collaboration with Sunnybrook Health Sciences Centre and The University of Illinois, aims to develop an accurate breast imaging approach for early identification of breast cancer patients' response to neoadjuvant chemotherapy (NAC). The QTI Breast Acoustic CT™ System has been successfully used to collect high-resolution breast images with biomarkers sensitive to cancer. The next phase will incorporate AI/ML techniques to improve NAC efficacy estimates based on quantitative biomarkers from QTI scans and backscatter analysis.